Company: RGBP
Filing Date: 2025-02-24
Form Type: 253G1
Source: 0001493152-25-008067
Chunk: 18

Company: Regen BioPharma Inc
Filing Date: 2025-02-24
Form: 253G1
Chunk 18
---
 |     | $400,000                                                                                                                                
 assuming all 10,000,000 Shares are purchased                                                                                            
 in the Offering. at $0.04 per share                                                                                                     |
| Shares                                         
 of Common Stock Outstanding after the Offering |     | As                                                                                                                                      
 of the date of this Offering Circular, the Company has 21,554,705 shares of common stock outstanding. If all Shares                     
 are sold in the Offering, the Company will have an aggregate of 31,554,745 shares of common stock issued and outstanding,               
 assuming no conversion of any outstanding convertible instruments.                                                                      |
| How                                            
 to Subscribe                                   |     | To                                                                                                                                      
 subscribe for Shares in the Offering, complete a subscription agreement (the form is included with this Offering Circular), and deliver 
 it, together with the total subscription price for all the Shares you wish to purchase, on or before the Closing Date, as defined       
 below, to the Company                                                                                                                   |

The offering will commence within two days of qualification by the
United States Securities and Exchange Commission and will terminate 90 days after qualification. The Company will retain all proceeds
received from the shares sold in this offering. The Company has not made any arrangements to place the proceeds in an escrow or trust
account. Any proceeds received in this offering may be immediately used by the Company in its sole discretion. There are no minimum purchase
requirements for each investor. All proceeds retained by the Company may not be sufficient to continue operations. Subscription proceeds
will not be escrowed and will be immediately available to the Company.

* includes 15,426,386 common shares to be distributed as a dividend to all shareholders of record as of October 17, 2024 (“Record Date”) to be paid to shareholders on or about November 1, 2024

| 17 |

DISQUALIFYING EVENTS AND BAD ACTOR DISCLOSURE

Regulation A+ promulgated under the Securities Act prohibit an issuer from claiming an exemption from registration of its securities under such rule if the issuer, or any of its predecessors, any affiliated issuer, any director, executive officer, other officer participating in the offering of the interests, general partner or managing member of the issuer, any beneficial owner of 20% or more of the voting power of the issuer’s outstanding voting securities, any promoter connected with the issuer in any capacity as of the date hereof, an investment manager of the issuer any person that has been or will be paid (directly or indirectly) remuneration for solicitation of